Victor Gehling

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Maia Vinogradova, Victor Gehling, Amy Gustafson et al. · Nature Chemical Biology · 2016 · 343 citations · Full text

Drug-tolerant Cancer Cells, Medicine, Anti-cancer Agent +7

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Brian K. Albrecht, Victor Gehling, Michael C. Hewitt et al. · Journal of Medicinal Chemistry · 2016 · 214 citations · Full text

Immunology, Pharmacotherapy, Tumor Biology +22

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 214 citations · Full text

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

William D. Bradley, Shilpi Arora, Jennifer Busby et al. · Chemistry & Biology · 2014 · 148 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors

Victor Gehling, Michael C. Hewitt, Rishi G. Vaswani et al. · ACS Medicinal Chemistry Letters · 2013 · 103 citations · Full text

Medicinal Chemistry, Drug Target, Bioorganic Chemistry +15